JANX
Janux TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Composite grade D from latest DB weights. Momentum 23.5 / Value 57.6
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
24
Value
58
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $49.50
Why
Momentum24 · Δ7d +2.9
Value58 · Δ7d +0.1
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
24
52% active weight
Current posture
7d trendFlat
Δ7d
+2.9
Δ21d
-0.1
Value
58
48% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.3
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 23.5 / Value 57.6
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$840.36M
Beta
2.88
Shares Out
60.15M
P/E (TTM) · Derived
-7.6
P/S (TTM)
82.70
P/FCF (TTM) · Derived
-11.87
Rev YoY
+2177.9%
EPS YoY
+23.7%
Gross Margin
-
Op Margin
-1442.9%
Net Debt
-$1.03B
Current Ratio
35.86
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology